Literature DB >> 34283088

Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation.

Hongmei Zheng1,2, Sumit Siddharth2, Sheetal Parida2, Xinhong Wu1, Dipali Sharma2.   

Abstract

Triple negative breast cancer (TNBC) is a heterogeneous disease and is highly related to immunomodulation. As we know, the most effective approach to treat TNBC so far is still chemotherapy. Chemotherapy can induce immunogenic cell death, release of damage-associated molecular patterns (DAMPs), and tumor microenvironment (TME) remodeling; therefore, it will be interesting to investigate the relationship between chemotherapy-induced TME changes and TNBC immunomodulation. In this review, we focus on the immunosuppressive and immunoreactive role of TME in TNBC immunomodulation and the contribution of TME constituents to TNBC subtype classification. Further, we also discuss the role of chemotherapy-induced TME remodeling in modulating TNBC immune response and tumor progression with emphasis on DAMPs-associated molecules including high mobility group box1 (HMGB1), exosomes, and sphingosine-1-phosphate receptor 1 (S1PR1), which may provide us with new clues to explore effective combined treatment options for TNBC.

Entities:  

Keywords:  immunomodulation; triple negative breast cancer; tumor microenvironment

Year:  2021        PMID: 34283088     DOI: 10.3390/cancers13133357

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  10 in total

Review 1.  Nanobiotherapeutic strategies to target immune microenvironment of triple-negative breast cancer.

Authors:  Qing Chang; Liang Chang; Mo Li; Liwen Fan; Shunchao Bao; Xinyu Wang; Linlin Liu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

2.  Involvement of Mitochondrial Mechanisms and Cyclooxygenase-2 Activation in the Effect of Desethylamiodarone on 4T1 Triple-Negative Breast Cancer Line.

Authors:  Ferenc Gallyas; Fadi H J Ramadan; Kitti Andreidesz; Eniko Hocsak; Aliz Szabo; Antal Tapodi; Gyongyi N Kiss; Katalin Fekete; Rita Bognar; Arpad Szanto; Zita Bognar
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

3.  Identification of a Lipid Metabolism-Associated Gene Signature Predicting Survival in Breast Cancer.

Authors:  Mingkai Gong; Xiangping Liu; Wu Yang; Hongming Song; Xian Zhao; Xiancheng Ai; Shuo Wang; Haibo Wang
Journal:  Int J Gen Med       Date:  2021-12-09

Review 4.  Hyaluronan Functions in Wound Repair That Are Captured to Fuel Breast Cancer Progression.

Authors:  Cornelia Tolg; Britney Jodi-Ann Messam; James Benjamin McCarthy; Andrew Cook Nelson; Eva Ann Turley
Journal:  Biomolecules       Date:  2021-10-20

5.  Immunogenic Cell Death-Relevant Damage-Associated Molecular Patterns and Sensing Receptors in Triple-Negative Breast Cancer Molecular Subtypes and Implications for Immunotherapy.

Authors:  Ming Xu; Jin-Hua Lu; Ya-Zhen Zhong; Jing Jiang; Yue-Zhong Shen; Jing-Yang Su; Sheng-You Lin
Journal:  Front Oncol       Date:  2022-04-04       Impact factor: 5.738

6.  5-Methoxytryptophan Sensitizing Head and Neck Squamous Carcinoma Cell to Cisplatitn Through Inhibiting Signal Transducer and Activator of Transcription 3 (STAT3).

Authors:  Yu-Chieh Su; Chih-Chun Wang; Jui-Hsi Weng; Shyh-An Yeh; Po-Jen Chen; Tzer-Zen Hwang; Huang-Chi Chen
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

Review 7.  Research progress on immunotherapy in triple‑negative breast cancer (Review).

Authors:  Xiaoxiao Zhang; Xueying Ge; Tinghan Jiang; Ruming Yang; Sijie Li
Journal:  Int J Oncol       Date:  2022-06-28       Impact factor: 5.884

8.  Multimodal Dimension Reduction and Subtype Classification of Head and Neck Squamous Cell Tumors.

Authors:  Jonathan E Bard; Norma J Nowak; Michael J Buck; Satrajit Sinha
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

9.  Prognostic Capability of TNBC 3-Gene Score among Triple-Negative Breast Cancer Subtypes.

Authors:  Jhajaira M Araujo; Gabriel De la Cruz-Ku; Melanie Cornejo; Franco Doimi; Richard Dyer; Henry L Gomez; Joseph A Pinto
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

Review 10.  Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma.

Authors:  Xiaozhuo Gao; Bo Gao; Shenglong Li
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.